GE Healthcare (Chalfont St. Giles, UK) Eisai Inc. (Woodcliff Lake, N.J.) ND Research collaboration agreement for use of the GE's PET amyloid imaging agent (18)flutemetamol in a Phase I trial testing E2609 for Alzheimer's disease Financial terms were not disclosed 4/25/13 GlaxoSmithKline plc (London) A*STAR's Institute of Chemical and Engineering Sciences (Singapore) ND Five-year agreement to develop new evidence-based formulations specifically for emerging markets EBFs are medicines reformulated

Arno Therapeutics Inc., of Parsippany, N.J., signed an agreement with Clarient Diagnostic Services Inc., a GE Healthcare company, to develop a diagnostic test for progesterone receptors in endometrial cancer

GE Healthcare, of Chalfont St. Giles, UK, and Eisai Inc., of Woodcliff Lake, N.J., inked a research collaboration agreement for use of the GE Healthcare investigational PET amyloid imaging agent

GE Healthcare, of Chalfont St. Giles, UK, and Eisai Inc., of Woodcliff Lake, N.J., inked a research collaboration agreement for use of the GE Healthcare investigational PET amyloid imaging agent

Inc. (Whitehouse Station, N.J.) GE Healthcare (Princeton, N.J.) ND Collaboration, license and supply agreement for the use of

The following year, Immunomedics received its first $5 million milestone payment from Nycomed and signed a collaboration with GE Healthcare to discover diagnostic agents using Immunomedics' F-18 labeling technology

Pither was involved in the development of a 18F-PET radiopharmaceutical for imaging amyloid deposition in the brains of Alzheimer's disease patients in his former post at GE Healthcare (Medical Diagnostics), and as he noted, PET is high cost and low volume, and so not accessible to most people

Pither was involved in the development of a 18F-PET radiopharmaceutical for imaging amyloid deposition in the brains of Alzheimer's disease patients in his former post at GE Healthcare (Medical Diagnostics), and as he noted, PET is high cost and low volume, and so not accessible to most people

Inc. (Whitehouse Station, N.J.) GE Healthcare (Princeton, N.J.) ND Collaboration, license and supply agreement for the use of

Inc., of Whitehouse Station, N.J., and GE Healthcare, of Princeton, N.J., inked a clinical study collaboration, license and supply agreement for the use of

It's deeply regrettable when that happens," said Nigel Darby, chief technology officer of GE Healthcare's life sciences division, which has its roots in the former Pharmacia Biotech facility in Uppsala

GE Healthcare, of Chalfont St Giles, UK, reported at the 16th Congress of the European Federation of Neurological Societies in Stockholm, Sweden, pooled results from a Phase III brain autopsy and biopsy studies on the investigational PET amyloid imaging agent

GE Healthcare, of Chalfont St Giles, UK, reported at the 16th Congress of the European Federation of Neurological Societies in Stockholm, Sweden, pooled results from a Phase III brain autopsy and biopsy studies on the investigational PET amyloid imaging agent

Ltd. (Tokyo) ND Supply agreement for Abilify OD Tablets (orally disintegrating tablets) using Catalent's Zydis fast-dissolve drug delivery technology Otsuka developed Abilify OD for schizophrenia and bipolar disorder 7/25/12 iBio Inc. (Newark, Del.) GE Healthcare (Chalfont St. Giles, UK) ND Global alliance to commercialize plant-based technologies for the manufacture of biopharmaceuticals and vaccines The deal builds on the companies' 2010 development and marketing agreement

GE Healthcare, of Princeton, N.J., said the label for contrast agent Optison (perflutren protein-Type A microspheres injectable suspension, USP) was updated to include warnings about serious cardiopulmonary reactions

iBio Inc., of Newark, Del., and GE Healthcare, of Chalfont St. Giles, UK, the health care business of GE, said they inked a global alliance to commercialize plant-based technologies for the manufacture of biopharmaceuticals and vaccines...The deal builds on the companies' 2010 development and marketing agreement and combines iBio's plant-based vaccine manufacturing platform, iBioLaunch, with GE Healthcare's capabilities in start-to-finish technologies

Total Value in 2012: $4,336M* Number of Deals in 2012: 142 Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date JUNE Affibody AB (Stockholm, Sweden) GE Healthcare (Chafont St. Giles, UK) ND Collaboration to develop a HER2-targeted PET imaging agent, to begin clinical trials later this year The trials will seek to confirm HER2 status in patients with breast cancer recurrence 6/8/12 Amarantus BioSciences Inc. (Sunnyvale, Calif.) Banyan Biomarkers Inc. (Alachua, Fla

MannKind also is eligible for tiered royalties on sales of products and a percentage of sublicensing revenue 5/1/12 JUNE Affibody AB (Stockholm, Sweden) GE Healthcare (Chafont St. Giles, UK) ND Collaboration to develop a HER2-targeted PET imaging agent, to begin clinical trials later this year The trials will seek to confirm HER2 status in patients with breast cancer recurrence 6/8/12 Amarantus BioSciences Inc. (Sunnyvale, Calif.) Banyan Biomarkers Inc. (Alachua, Fla.) ND Collaboration to

Affibody AB, of Stockholm, Sweden, and GE Healthcare, of Chafont St. Giles, UK, will collaborate to develop a HER2-targeted PET imaging agent, to begin clinical trials later this year